Michigan doctors say these 5 changes are coming to health care in 2026

Michigan health leaders warn 2026 could bring material shifts in U.S. healthcare: sharply rising insurance premiums are creating an affordability crisis while long-standing vaccine recommendations may be substantially revised. Clinicians expect accelerating adoption of artificial intelligence and other technologies to transform care delivery, and wider access to a class of weight-loss drugs that could materially affect the obesity epidemic and related healthcare utilization. These developments have public‑health and policy implications that could influence healthcare providers, payors and drug manufacturers over the coming year.

Analysis

Market structure: The 2026 mix—rapid GLP‑1 adoption, AI tooling, vaccine guideline shifts and rising premiums—creates clear winners (GLP‑1 makers NVO, LLY; AI infrastructure NVDA; healthcare IT ORCL) and losers (hospital volumes for chronic disease, select device names JNJ/MDT; retail pharmacy margin pressure). Pricing power concentrates: drugmakers can sustain premium pricing near-term with ~20–40% revenue growth potential vs. durable margin pressure for payors if regulatory caps emerge. On supply/demand, expect constrained short‑term supply for popular injectables (3–9 months SKU tightness) and greater long‑term demand elasticity as coverage expands.

Risk assessment: Tail risks include aggressive Medicare/CMS intervention (price negotiation or coverage limits) and rapid adverse-adverse events for GLP‑1s triggering prescribing pauses—both 10–25% probability but >50% P&L impact for exposed long positions. Time horizons split: immediate (30–90 days) — CMS/FDA guidance and 2026 premium filings; short (3–12 months) — sales ramp and inventory; long (1–3 years) — chronic disease prevalence shifts. Hidden dependencies: provider capacity, distribution bottlenecks, and AI regulatory approvals; catalysts include FDA label expansions and CMS coverage decisions.

Trade implications: Favor concentrated, size‑controlled longs in NVO/LLY (0.5–3% each) and NVDA (1–2%) with hedges; use 9–18 month call spreads to cap cost ahead of anticipated catalysts (FDA/CMS). Consider modest underweights or pair shorts in payer/retail pharmacy (UNH/CVS 1–2% short exposure) vs. GLP‑1 makers to express regulatory risk. Rotate into healthcare IT (ORCL 1–2%) and imaging SaaS names to capture AI adoption.

Contrarian angles: Consensus may overestimate persistent top‑line growth for GLP‑1s without factoring coverage limits and adherence drop‑off (historical weight‑loss therapy discontinuation >50% by year 2). AI winners extend beyond NVDA to software integrators and mid‑cap imaging firms—those are underpriced relative to chips. Unintended consequence: successful widespread weight‑loss therapy could depress demand for some device and drug franchises over 3–5 years, creating long alpha opportunities to short legacy chronic‑care exposures.

Key Decisions for Investors

• Establish a 2% long position in NVO (Novo Nordisk) and a 1.5% long in LLY (Eli Lilly) using 9–12 month call spreads (buy 12‑month ATM call, sell a 30–40% OTM call) to capture expected GLP‑1 sales growth while capping downside if CMS intervenes; review after quarterly sales releases (next 60–90 days).
• Allocate 1.5–2% to NVDA via a 12‑18 month LEAP call (or a bull call spread to limit premium) to play AI adoption in diagnostics and clinical workflow, with a sell/trim trigger if NVDA rallies >40% from entry or ahead of major analyst re-rates.
• Initiate a pair trade: long ORCL (1%) to capture Cerner synergies and AI EMR monetization, short UNH (1%) to express regulatory/political risk to payors; rebalance if CMS announces explicit GLP‑1 coverage policy within the next 30–90 days.
• Reduce exposure to device names with high chronic‑disease revenue sensitivity (e.g., trim JNJ/MDT positions by 1–2% of portfolio) and redeploy into healthcare IT/AI names over 3–12 months as GLP‑1 adoption data and adherence trends become clearer.